## REGN: Regeneron Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.46 indicates fundamental undervaluation. Quality metrics strong (ROE 15%). Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($726.60)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Regeneron (REGN) Valuation Check After Lynozyfic Trial Success and New Gene Writing Collaboration**
- Source: Simply Wall Street | 20251218T093235 | Bullish | Relevance: 100%
- Regeneron Pharmaceuticals' recent success with its multiple myeloma candidate Lynozyfic and new gene writing collaboration has caused its shares to rise. Despite a 26.66% return in 90 days, the company is still considered 4% undervalued with a fair value of $781.13 per share, primarily driven by expectations of durable earnings power and improved net profit margins. However, potential headwinds for Eylea or late-stage pipeline disappointments could impact this outlook.

**2. Regeneron (REGN) Valuation Check After Lynozyfic Trial Success and New Gene Writing Collaboration**
- Source: Simply Wall Street | 20251218T090843 | Bullish | Relevance: 100%
- Regeneron Pharmaceuticals (REGN) has garnered investor attention following promising Phase 1/2 data for its multiple myeloma candidate, Lynozyfic, and new developments in gene writing. Despite a 26.66% share price return in the last 90 days and a 54.2% five-year total shareholder return, the company is still considered 4% undervalued with a narrative fair value of $781 per share, suggesting patient upside driven by strong earnings power. However, potential challenges like Eylea headwinds or pipeline disappointments could impact this premium valuation.

**3. Alvotech, Teva reach settlement with Regeneron over Eylea biosimilar AVT06 in U.S. (TEVA:NYSE)**
- Source: Seeking Alpha | 20251219T100952 | Neutral | Relevance: 100%
- Alvotech and Teva Pharmaceuticals have reached a settlement and license agreement with Regeneron Pharmaceuticals regarding AVT06, Alvotechâ€™s proposed biosimilar to Eylea (aflibercept), in the United States. This agreement grants a license entry date for the biosimilar.

**4. Woodstock Corp Acquires 8,589 Shares of Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251217T143458 | Bullish | Relevance: 100%
- Woodstock Corp significantly increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 107.1% during the third quarter, purchasing an additional 8,589 shares to own 16,610 shares valued at $9.34 million. This move comes amidst mixed insider activity, with significant sales by a director and a VP, while institutional ownership remains high at 83.31%. Analysts have a "Moderate Buy" rating on REGN with an average price target of $779.45.

**5. Sicart Associates LLC Makes New $3.93 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251217T123820 | Somewhat-Bearish | Relevance: 100%
- Sicart Associates LLC has made a new investment of $3.93 million in Regeneron Pharmaceuticals (NASDAQ:REGN) during the third quarter of 2025, acquiring 6,981 shares. This comes as Regeneron outperformed quarterly estimates, and analysts have issued a "Moderate Buy" consensus with an average price target of $779.45. Despite some insider selling, institutional investors now own 83.31% of the company's stock.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 6, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $768 | $767 | +0% |
| 2025-12-10 | Wells Fargo | $745 | $700 | +6% |
| 2025-12-04 | Canaccord Genui | $1057 | $850 | +24% |
| 2025-12-04 | BMO Capital | $850 | $725 | +17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-04 | Canaccord Genui | main | Buy |
| 2025-12-04 | BMO Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 9 ($97.67M) |
| Sells | 15 ($32.83M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (-4.0%)
- Blackrock Inc.: 8.6% (-4.7%)
- JPMORGAN CHASE & CO: 7.9% (+106.7%)
- State Street Corpora: 4.5% (-2.9%)
- Dodge & Cox Inc.: 4.4% (+18.9%)

### Key Risks

1. Heavy insider selling: $33M sold (15 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 6 raises (avg +13%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.46 suggests fair value with growth premium. Quality metrics strong (margin 32%). Balance sheet: strong liquidity (4.1x), low leverage (D/E 0.30), $1.4B free cash flow. Analyst sentiment positive (6 raises, avg +13%). Insider buying signal ($97.7M), management confidence. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $81.4B |
| Beta | 0.37 |
| 52W Range | $476.49 - $790.98 |
| Short Interest | 3.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.46 |
| Forward P/E | 20.0 |
| Current P/E | 17.8 |
| YoY Growth | -11.2% |
| EPS Direction | RISING |

### Technicals

MRS_20 stable at 2.7% (minimal 5-day change). Below STRENGTH zone by 1.3pp (needs >4.0% for momentum thesis). MRS_5 at 0.8% confirms short-term momentum alignment. AM_20 at 3.1% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-1.37), momentum weakening. OFD pattern: +MTH (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.70% (CS: 75) | Neutral |
| RSI_14 | 64.2 | Neutral |
| MACD Histogram | -1.37 | Bearish |
| vs SMA20 | 1.031x | Above |
| vs SMA50 | 1.133x | Above |
| vs SMA200 | 1.278x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $767.96
- **Stop Loss:** $726.60 (5.4% risk)
- **Target:** $850.68 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 29
- **Position Value:** $22,270.84
- **Portfolio %:** 22.27%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-03 (Est: $10.77)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.64 | $11.83 | +22.7% |
| 2025Q2 | $8.44 | $12.89 | +52.7% |
| 2025Q1 | $8.48 | $8.22 | -3.0% |
| 2024Q4 | $11.19 | $12.07 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*